Malaria treatment in Nigeria remains one of the most frequently performed clinical interventions in the country. Nigeria accounts for approximately 25.9 percent of global malaria cases and 31 percent of global malaria deaths, making it the highest-burden country for this disease in the world.(1) Every clinician practicing in Nigeria, regardless of specialty, will encounter malaria regularly and must be confident in applying the correct treatment guidelines.

Despite the availability of effective treatments, malaria continues to kill Nigerians every day. Many of these deaths are preventable. Treatment delays, wrong drug choices, incorrect dosing, and failure to recognise severe malaria features are the most common reasons patients deteriorate and die from a curable disease.

This guide provides a complete, evidence-based reference for malaria treatment in Nigeria for adults, children, and special populations, based on WHO August 2025 guidelines and the NMEP guidelines. For instant access to treatment protocols at the point of care, visit Medituri Treatment Guidelines at medituri.com.

Drug Class: Antimalarial Agents

Plasmodium falciparum is responsible for the overwhelming majority of malaria cases and deaths in Nigeria. Therefore, all treatment recommendations in this guide refer to P. falciparum malaria unless otherwise stated. The main drug classes used in Nigeria include artemisinin-based combination therapies (ACTs), injectable artesunate for severe disease, and supportive medications.(2)

Step 1: Confirm the Diagnosis Before Treatment

All patients with suspected malaria in Nigeria should be tested with a malaria rapid diagnostic test (RDT) or blood film microscopy before treatment is initiated wherever diagnostic capacity is available.(2) However, where testing is not available and clinical suspicion is high, particularly in children under five years with fever, treatment should not be delayed.

Symptoms of uncomplicated malaria include fever, chills, headache, body aches, nausea, and vomiting. Features suggesting severe malaria require immediate escalation and parenteral treatment.

Malaria Treatment Nigeria: First-Line Drug for Uncomplicated Malaria

According to the WHO Guidelines for Malaria, August 2025, artemether-lumefantrine (AL) is the recommended first-line treatment for uncomplicated P. falciparum malaria in Nigeria for adults and children.(2) The NMEP guidelines are aligned with this recommendation.(3)

AL is given as a six-dose course over three days. Furthermore, it must always be taken with food or a fat-containing drink to ensure adequate absorption of lumefantrine. Taking AL on an empty stomach significantly reduces bioavailability and increases the risk of treatment failure.

Artemether-Lumefantrine Dosing by Weight: Quick Reference

Weight Band	Tablets Per Dose	Number of Doses	Total Tablets
5 to 14 kg	1 tablet	6 doses over 3 days	6 tablets
15 to 24 kg	2 tablets	6 doses over 3 days	12 tablets
25 to 34 kg	3 tablets	6 doses over 3 days	18 tablets
35 kg and above	4 tablets	6 doses over 3 days	24 tablets

Each tablet of AL contains artemether 20 mg and lumefantrine 120 mg. Doses are given at hours 0, 8, 24, 36, 48, and 60.(2)

Alternative ACTs when AL is unavailable: artesunate-amodiaquine (ASAQ), artesunate-mefloquine (ASMQ), and dihydroartemisinin-piperaquine (DHA-PPQ). These are all given as once-daily regimens over three days. Artesunate-amodiaquine is the most widely available alternative in Nigeria.(2,3)

Severe Malaria Treatment Nigeria: Recognise and Act Immediately

Severe malaria is a medical emergency. Any delay in initiating parenteral treatment increases the risk of death. Therefore, every clinician in Nigeria must know the features of severe malaria and how to respond without hesitation.

11 Features of Severe Malaria Every Nigerian Clinician Must Know

1. Impaired consciousness or coma (cerebral malaria)
2. Prostration: inability to sit, stand, or walk without assistance
3. Multiple seizures (more than two in 24 hours)
4. Respiratory distress: deep, laboured breathing
5. Severe anaemia: haemoglobin below 5 g/dL with high parasite density
6. Hypoglycaemia: blood glucose below 2.2 mmol/L
7. Haemoglobinuria: dark cola-coloured urine
8. Acute kidney injury: oliguria or anuria
9. Pulmonary oedema or acute respiratory distress syndrome
10. Hyperparasitaemia: greater than 5 percent of red blood cells parasitised on blood film
11. Jaundice with evidence of organ dysfunction

If any feature of severe malaria is present, do not give oral treatment. Initiate parenteral artesunate immediately and refer to the nearest facility with ICU or high dependency care capacity.

Parenteral Artesunate: First-Line for Severe Malaria

Injectable artesunate is the WHO-recommended first-line treatment for severe malaria in all patients including adults, children, infants, and pregnant women in all trimesters.(2) It is superior to quinine in reducing mortality, faster at clearing parasites, better tolerated, and easier to administer.(4)

Patient Group	Dose	Timing	Route
Adults and children 20 kg and above	2.4 mg/kg per dose	At 0h, 12h, 24h, then once daily	IV or IM
Children below 20 kg	3 mg/kg per dose	At 0h, 12h, 24h, then once daily	IV or IM

Parenteral artesunate must be continued for a minimum of 24 hours and until the patient can tolerate oral medication. Once the patient improves and can swallow, complete treatment with a full 3-day course of an oral ACT.(2)

Managing Severe Malaria Without Artesunate

If injectable artesunate is unavailable: use intramuscular artemether as the first alternative. Intravenous quinine is the second alternative if neither artesunate nor artemether is available. Treatment must not be withheld while awaiting drug procurement.

Pre-Referral Treatment for Severe Malaria

In settings where complete parenteral treatment is not immediately available, a single intramuscular dose of artesunate should be given and the patient referred immediately to a higher facility.(2) In children between six months and six years, rectal artesunate is recommended as a pre-referral intervention when IM artesunate is not available, followed by immediate referral.

5 Important Drug Interactions in Malaria Treatment Nigeria

• AL and rifampicin: Rifampicin induces CYP3A4 and significantly reduces lumefantrine plasma levels, potentially leading to treatment failure. Avoid co-administration in patients on TB treatment where possible.(5)
• AL and efavirenz or nevirapine: Both antiretrovirals reduce lumefantrine exposure. In HIV-malaria co-infected patients on these ARVs, consider artesunate-amodiaquine as an alternative ACT.(5)
• Quinine and mefloquine: Additive QT prolongation and risk of cardiac arrhythmias. Do not co-administer.
• Quinine and beta-blockers or digoxin: Risk of cardiac conduction abnormalities. Monitor ECG closely.
• Primaquine and G6PD deficiency: Primaquine causes severe haemolysis in G6PD-deficient patients. Always test G6PD status before prescribing. Primaquine is contraindicated in pregnancy.

Check all drug interactions instantly using the Medituri Drug Interaction Checker at medituri.com.

Adverse Effects of Antimalarial Drugs

Artemether-Lumefantrine

• Nausea, vomiting, and abdominal discomfort: common, particularly when taken without food
• Headache and dizziness: usually mild and self-limiting
• QT prolongation: rare at standard doses but clinically relevant in patients with pre-existing cardiac disease
• Post-treatment delayed haemolytic anaemia: rare but reported after parenteral artesunate in high-parasitaemia patients; monitor haemoglobin weekly for four weeks after parenteral treatment

Quinine

• Cinchonism: tinnitus, headache, nausea, and visual disturbances at therapeutic doses
• Hypoglycaemia: particularly dangerous in pregnant women and children; monitor blood glucose regularly during IV quinine
• QT prolongation: monitor ECG during intravenous administration

Monitoring and Prescribing Tips

• Always confirm diagnosis with an RDT or blood film before treating whenever testing is available. Presumptive treatment without testing drives unnecessary drug use and masks other diagnoses.
• Monitor blood glucose in all patients with severe malaria and in pregnant women receiving quinine. Hypoglycaemia is a preventable cause of death in malaria.
• Assess for anaemia at presentation. Severe anaemia with haemoglobin below 5 g/dL and respiratory distress requires urgent blood transfusion alongside antimalarial treatment.
• Follow up after treatment to confirm parasite clearance. Repeat blood film or RDT at day 3 for patients treated for severe malaria or where treatment failure is suspected.
• Do not use artemisinin monotherapy. Monotherapy drives resistance. Always use a full ACT regimen as recommended.
• In patients on antiretroviral therapy, check for drug interactions before selecting an ACT. Consider ASAQ over AL where efavirenz or nevirapine is part of the ARV regimen.

5 Clinical Mistakes to Avoid in Malaria Treatment in Nigeria

1. Giving parenteral artemether for uncomplicated malaria. Oral ACT is the correct treatment for uncomplicated malaria. Reserve parenteral drugs for severe disease only.
2. Giving AL on an empty stomach. A common reason for treatment failure in Nigerian outpatient settings is patients taking AL without food. Counsel every patient explicitly on this point.
3. Dosing AL by age instead of weight in children. Always confirm the child’s weight before prescribing. Dosing by age is a common source of underdosing in Nigerian paediatric practice.
4. Delaying IV access in a child with severe malaria. Where IV access is difficult, IM artesunate is equally effective and easier to administer. Do not delay treatment.
5. Not having rectal artesunate available at PHC level. Rectal artesunate suppositories are a life-saving pre-referral tool for children aged 6 months to 6 years. Every PHC in Nigeria should have access to this intervention.

Nigeria and West Africa Context

Nigeria has the world’s highest malaria burden, accounting for approximately 27 percent of global malaria cases.(1) The Nigeria National Malaria Elimination Programme (NMEP) has adopted WHO-aligned treatment guidelines, with artemether-lumefantrine as the first-line treatment for uncomplicated malaria and injectable artesunate as the first-line treatment for severe malaria.(3)

However, significant challenges persist in Nigerian clinical practice. A study evaluating compliance with NMEP guidelines in a southern Nigerian state found that more than 60 percent of uncomplicated malaria cases were being treated with parenteral artemether instead of oral ACT, contrary to guidelines.(6) Furthermore, injectable artesunate was not being used as first-line for severe malaria in approximately 40 percent of secondary health facilities surveyed.

Implementation Gaps and Drug Availability

These findings highlight a critical implementation gap. The drugs and guidelines exist. In addition, the knowledge and practice gap at the facility level continues to cost lives. Consistent adherence to evidence-based treatment protocols is therefore the most impactful intervention available to Nigerian clinicians right now.

Drug availability also remains a challenge. While AL and injectable artesunate are on the National List of Essential Medicines and are NAFDAC-approved, stock-outs occur regularly at primary health centres and rural facilities. Clinicians in these settings must know the alternatives and have clear referral pathways for severe malaria cases.

Conclusion

Malaria treatment in Nigeria is straightforward when the correct guidelines are followed consistently. Artemether-lumefantrine is the first-line treatment for uncomplicated malaria in all non-pregnant adults and children. Injectable artesunate is the first-line treatment for severe malaria in all patients. Oral ACT should never be used for severe malaria, and parenteral drugs should not be used routinely for uncomplicated disease.

In conclusion, the key to reducing malaria deaths in Nigeria is not waiting for new drugs. The drugs we have are highly effective. What is needed is consistent, correct, and timely application of the treatment guidelines that already exist. Every clinician who follows these guidelines correctly is saving lives.

Access Malaria Treatment Guidelines on Medituri

For quick access to malaria treatment protocols, dosing references, drug interaction checks, and evidence-based clinical guidelines at the point of care, visit the Medituri Treatment Guidelines and Drug Database at medituri.com. Medituri gives healthcare professionals in Nigeria and West Africa instant access to reliable clinical drug information on any device, any time.

Frequently Asked Questions about Malaria Treatment in Nigeria

Q: What is the first-line treatment for malaria in Nigeria?

A: Artemether-lumefantrine (AL) is the WHO-recommended first-line treatment for uncomplicated P. falciparum malaria in Nigeria for adults and children. It is given as a six-dose course over three days and must always be taken with food to ensure adequate absorption.

Q: What is the treatment for severe malaria in Nigeria?

A: Injectable artesunate is the first-line treatment for severe malaria in Nigeria for all patients including adults, children, and pregnant women. It is given intravenously or intramuscularly at 2.4 mg/kg per dose for adults and children above 20 kg, and 3 mg/kg per dose for children below 20 kg.

More Clinical Questions about Malaria Treatment Nigeria

Q: What are the features of severe malaria?

A: Features of severe malaria include impaired consciousness or coma, prostration, multiple seizures, respiratory distress, severe anaemia, hypoglycaemia, haemoglobinuria, acute kidney injury, pulmonary oedema, hyperparasitaemia, and jaundice with organ dysfunction. Any of these features requires immediate parenteral treatment.

Q: What is the dose of artemether-lumefantrine in children?

A: Artemether-lumefantrine dosing in children is based on weight. Children 5 to 14 kg receive 1 tablet per dose, 15 to 24 kg receive 2 tablets, 25 to 34 kg receive 3 tablets, and children 35 kg and above receive 4 tablets. Six doses are given over three days at hours 0, 8, 24, 36, 48, and 60.

Q: Can artemether-lumefantrine be given on an empty stomach?

A: No. Artemether-lumefantrine must always be taken with food or a fat-containing drink. Taking AL on an empty stomach significantly reduces lumefantrine absorption and bioavailability, which can lead to treatment failure. This is one of the most common prescribing errors in Nigerian clinical practice.

Q: What is the alternative to artemether-lumefantrine for malaria in Nigeria?

A: When artemether-lumefantrine is unavailable, alternative WHO-accepted ACTs include artesunate-amodiaquine (ASAQ), artesunate-mefloquine (ASMQ), and dihydroartemisinin-piperaquine (DHA-PPQ), all given as once-daily regimens over three days. Artesunate-amodiaquine is the most widely available alternative in Nigeria.

References

1. World Health Organization. World Malaria Report 2024. Geneva: WHO; 2024. Available from: https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024
2. World Health Organization. WHO Guidelines for Malaria. Geneva: WHO; 13 August 2025. Available from: https://www.who.int/publications/i/item/guidelines-for-malaria
3. Nigeria National Malaria Elimination Programme. National Malaria Strategic Plan. Abuja: Federal Ministry of Health; 2021. Available from: https://www.nmep.gov.ng
4. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647-1657.
5. Byakika-Kibwika P, Lamorde M, Mayito J, et al. Significant pharmacokinetic interactions between artemether-lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother. 2012;67(9):2213-2221.
6. Chukwuocha UM, Okorie PC, Dozie IN, et al. Implementation of the revised national malaria control guidelines: compliance and challenges in public health facilities in a southern Nigerian state. Pan Afr Med J. 2023;46:112.